Cargando…
PTH Assays: Understanding What We Have and Forecasting What We Will Have
Parathyroid hormone (PTH) assays have evolved continuously for the last 50 years. Since the first radioimmunoassay was described in 1963, several assays based on immunological identification have been published (first generation assays). The routine assays used nowadays are immunometric “sandwich-ty...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324155/ https://www.ncbi.nlm.nih.gov/pubmed/22548199 http://dx.doi.org/10.1155/2012/523246 |
_version_ | 1782229286208405504 |
---|---|
author | Vieira, Jose Gilberto H. |
author_facet | Vieira, Jose Gilberto H. |
author_sort | Vieira, Jose Gilberto H. |
collection | PubMed |
description | Parathyroid hormone (PTH) assays have evolved continuously for the last 50 years. Since the first radioimmunoassay was described in 1963, several assays based on immunological identification have been published (first generation assays). The routine assays used nowadays are immunometric “sandwich-type”. They are based on two different monoclonal antibodies, one amino-terminal and the other carboxyl terminal specific. These second generation assays are widely available and adapted to most of the automation platforms. The specificity of the amino terminal antibody defines if the immunometric assay measures only the bioactive PTH circulating form (including the first amino terminal amino acids) or the “intact” PTH, which includes, besides bioactive PTH, other “long” carboxyl-terminal forms, for example, 7–84-PTH. Assays for “intact” PTH are the most commonly available and the potential advantage of the bioactive PTH assays is still debatable. Next generation of assays will be based on different principles, mainly mass spectrometry in samples submitted to a prior purification and fragmentation steps. These assays will provide information about the whole spectra of PTH peptides in circulation, with a significant increase of the information regarding this biologically important peptide hormone. |
format | Online Article Text |
id | pubmed-3324155 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-33241552012-04-30 PTH Assays: Understanding What We Have and Forecasting What We Will Have Vieira, Jose Gilberto H. J Osteoporos Review Article Parathyroid hormone (PTH) assays have evolved continuously for the last 50 years. Since the first radioimmunoassay was described in 1963, several assays based on immunological identification have been published (first generation assays). The routine assays used nowadays are immunometric “sandwich-type”. They are based on two different monoclonal antibodies, one amino-terminal and the other carboxyl terminal specific. These second generation assays are widely available and adapted to most of the automation platforms. The specificity of the amino terminal antibody defines if the immunometric assay measures only the bioactive PTH circulating form (including the first amino terminal amino acids) or the “intact” PTH, which includes, besides bioactive PTH, other “long” carboxyl-terminal forms, for example, 7–84-PTH. Assays for “intact” PTH are the most commonly available and the potential advantage of the bioactive PTH assays is still debatable. Next generation of assays will be based on different principles, mainly mass spectrometry in samples submitted to a prior purification and fragmentation steps. These assays will provide information about the whole spectra of PTH peptides in circulation, with a significant increase of the information regarding this biologically important peptide hormone. Hindawi Publishing Corporation 2012 2012-04-03 /pmc/articles/PMC3324155/ /pubmed/22548199 http://dx.doi.org/10.1155/2012/523246 Text en Copyright © 2012 Jose Gilberto H. Vieira. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Vieira, Jose Gilberto H. PTH Assays: Understanding What We Have and Forecasting What We Will Have |
title | PTH Assays: Understanding What We Have and Forecasting What We Will Have |
title_full | PTH Assays: Understanding What We Have and Forecasting What We Will Have |
title_fullStr | PTH Assays: Understanding What We Have and Forecasting What We Will Have |
title_full_unstemmed | PTH Assays: Understanding What We Have and Forecasting What We Will Have |
title_short | PTH Assays: Understanding What We Have and Forecasting What We Will Have |
title_sort | pth assays: understanding what we have and forecasting what we will have |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324155/ https://www.ncbi.nlm.nih.gov/pubmed/22548199 http://dx.doi.org/10.1155/2012/523246 |
work_keys_str_mv | AT vieirajosegilbertoh pthassaysunderstandingwhatwehaveandforecastingwhatwewillhave |